Literature DB >> 18305011

5-Hydroxytryptamine lowers blood pressure in normotensive and hypertensive rats.

Jessica Diaz1, Wei Ni, Janice Thompson, Andrew King, Gregory D Fink, Stephanie W Watts.   

Abstract

Arterial hyper-responsiveness to 5-hydroxytryptamine (5-HT) is a hallmark of hypertension, and plasma levels of free 5-HT are elevated in hypertension. We hypothesized that chronic administration of 5-HT would cause blood pressure to 1) rise in normotensive rats and 2) rise significantly more in hypertensive rats. The deoxycorticosterone acetate (DOCA)-salt hypertensive and sham normotensive rat were used. Animals were implanted with minipumps that delivered 5-HT (or vehicle) at a rate of 25 microg/kg/min for 7 days. Free plasma 5-HT was elevated significantly by this protocol. Within 48 h, mean arterial blood pressure measured telemetrically decreased in sham (106 +/- 2 to 83 +/- 2 mm Hg) and in DOCA-salt hypertensive (166 +/- 9 to 112 +/- 3 mm Hg) rats; vehicle did not change blood pressure in either group. Ganglionic blockade (hexamethonium) reduced blood pressure to a greater magnitude in DOCA vehicle-administered rats (peak fall arterial pressure, 91 +/- 14 mm Hg) compared with DOCA 5-HT-administered rats (40 +/- 6 mm Hg). Maximal acetylcholine-induced (NO-dependent) relaxation in phenylephrine-contracted aortic strips was greater in 5-HT-administered (69.2 +/- 9.1% relaxation) versus vehicle-administered (39.7 +/- 14.2%) DOCA rats; aortic endothelial cell nitric oxide synthase expression was higher in the 5-HT- versus vehicle-administered DOCA-salt rats. In normotensive and DOCA-salt hypertensive rats, the nitric oxide synthase (NOS) inhibitor N(omega)-nitro-l-arginine (0.5 g/l in water) prevented the fall in blood pressure to 5-HT. We conclude that chronic exogenous 5-HT reduces blood pressure in normotensive and hypertensive rats through mechanisms critically dependent on NOS.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18305011     DOI: 10.1124/jpet.108.136226

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  23 in total

Review 1.  Serotonin and blood pressure regulation.

Authors:  Stephanie W Watts; Shaun F Morrison; Robert Patrick Davis; Susan M Barman
Journal:  Pharmacol Rev       Date:  2012-03-08       Impact factor: 25.468

2.  L-tryptophan ethyl ester dilates small mesenteric arteries by inhibition of voltage-operated calcium channels in smooth muscle.

Authors:  Ashok Jadhav; Wenbin Liang; John Balsevich; Guillaume Bastin; Jeff Kroetsch; Scott Heximer; Peter H Backx; Venkat Gopalakrishnan
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

Review 3.  5-hydroxtryptamine receptors in systemic hypertension: an arterial focus.

Authors:  Stephanie W Watts; Robert Patrick Davis
Journal:  Cardiovasc Ther       Date:  2011-02       Impact factor: 3.023

4.  5-HT causes splanchnic venodilation.

Authors:  Bridget M Seitz; Hakan S Orer; Teresa Krieger-Burke; Emma S Darios; Janice M Thompson; Gregory D Fink; Stephanie W Watts
Journal:  Am J Physiol Heart Circ Physiol       Date:  2017-06-16       Impact factor: 4.733

5.  Lack of the serotonin transporter (SERT) reduces the ability of 5-hydroxytryptamine to lower blood pressure.

Authors:  Robert Patrick Davis; A Elizabeth Linder; Stephanie W Watts
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-03-30       Impact factor: 3.000

6.  Creation of the 5-hydroxytryptamine receptor 7 knockout rat as a tool for cardiovascular research.

Authors:  Elena Y Demireva; Huirong Xie; Emma D Flood; Janice M Thompson; Bridget M Seitz; Stephanie W Watts
Journal:  Physiol Genomics       Date:  2019-05-24       Impact factor: 3.107

7.  5-HT does not lower blood pressure in the 5-HT7 knockout rat.

Authors:  Bridget M Seitz; Elena Y Demireva; Huirong Xie; Gregory D Fink; Teresa Krieger-Burke; William M Burke; Stephanie W Watts
Journal:  Physiol Genomics       Date:  2019-05-24       Impact factor: 3.107

Review 8.  Oh, the places you'll go! My many colored serotonin (apologies to Dr. Seuss).

Authors:  Stephanie W Watts
Journal:  Am J Physiol Heart Circ Physiol       Date:  2016-09-23       Impact factor: 4.733

9.  Serotonin 5-HT(2A) Receptor Function as a Contributing Factor to Both Neuropsychiatric and Cardiovascular Diseases.

Authors:  Charles D Nichols
Journal:  Cardiovasc Psychiatry Neurol       Date:  2009-10-13

10.  One-month serotonin infusion results in a prolonged fall in blood pressure in the deoxycorticosterone acetate (DOCA) salt hypertensive rat.

Authors:  Robert Patrick Davis; Theodora Szasz; Hannah Garver; Robert Burnett; Nathan R Tykocki; Stephanie W Watts
Journal:  ACS Chem Neurosci       Date:  2012-09-16       Impact factor: 4.418

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.